Search

CRx-139

It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

Tecadenoson

It is being developed by CV Therapeutics, Inc. … Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

SLx-4090

SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

Formic acid

It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. … It is commonly used as a preservative and antibacterial agent in livestock feed.

MRx-4DP0004

MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

cryopreserved human liver cells

Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. … The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation

Mitoquinone

Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.

Elvucitabine

Ligelizumab

efficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. … While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the

Tesofensine